David A. Siegel Intellia Therapeutics, Inc. Transaction History
Two Sigma Advisers, LP
- $46.1 Billion
- Q2 2025
A detailed history of David A. Siegel (Two Sigma Advisers, LP) transactions in Intellia Therapeutics, Inc. stock. As of the latest transaction made, Two Sigma Advisers, LP holds 2,093,017 shares of NTLA stock, worth $52.1 Million. This represents 0.04% of its overall portfolio holdings.
Number of Shares
2,093,017
Previous 1,982,317
5.58%
Holding current value
$52.1 Million
Previous $14.1 Million
39.29%
% of portfolio
0.04%
Previous 0.03%
Shares
27 transactions
Others Institutions Holding NTLA
# of Institutions
334Shares Held
97MCall Options Held
1.66MPut Options Held
1.03M-
Cathie Wood Ark Investment Management LLC | St. Petersburg, Fl13MShares$324 Million1.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA10.9MShares$270 Million0.0% of portfolio
-
Black Rock Inc. New York, NY9.6MShares$239 Million0.0% of portfolio
-
Morgan Stanley New York, NY4.12MShares$103 Million0.0% of portfolio
-
State Street Corp Boston, MA4.04MShares$101 Million0.0% of portfolio
About Intellia Therapeutics, Inc.
- Ticker NTLA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 76,011,800
- Market Cap $1.89B
- Description
- Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema, as well as other liver-focused programs comprising hemoph...